By Matthew Bultman ( December 9, 2015, 2:02 PM EST) -- The Patent Trial and Appeal Board on Tuesday refused a request from hedge fund manager Kyle Bass to review the validity of a patent on Horizon Pharma PLC's arthritis medication Vimovo, which Bass has called a "ridiculous" attempt to patent a combination of common drugs....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.